Cancer Monoclonal Antibodies Market
The global cancer monoclonal antibodies (mAbs) market has witnessed remarkable growth, driven by advances in biotechnology, rising cancer prevalence, and the increasing demand for targeted therapies. In 2021, the market was valued at $55.6 billion and is projected to reach $106.8 billion by 2031, growing at a CAGR of 7% from 2022 to 2031. This growth reflects the urgent need for innovative cancer treatments worldwide.
Comments
Post a Comment